XML 45 R22.htm IDEA: XBRL DOCUMENT
v3.25.4

Financial Instruments | 12 Months Ended
--- | ---
Dec. 31, 2025
Investments, All Other Investments [Abstract] |
Financial Instruments | Financial Instruments Fair Value Measurements The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market. The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, accounts payable and other liabilities, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and other liabilities, and loans receivable, approximate their fair values, and are primarily classified as Level 2. Contingent Consideration Contingent consideration relates to potential earn-out payments and future successful milestone payouts from previous business acquisitions. Contingent consideration is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates and are included in other income on the consolidated statements of loss. The inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition. The following table presents the changes in fair value of the liability for contingent consideration:
| December 31, 2024
| Liability at beginning of the year |  | Decrease in fair value of liability for contingent consideration |  | Repayment of contingent consideration |  | Liability at end of the year
Contingent consideration(i) | $ | 55,388 |  |  | $ | (47,301) |  |  | $ | — |  |  | $ | 8,087 |
(i) The fair value measurement was determined by estimating the expected future cash flows. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at ranging from 12.8% to 22%, which measures the risks inherent in each relevant future cash flows stream. In the year ended December 31, 2024, the fair value of the contingent consideration was adjusted to reflect the expected value due to the impact from the Company's ongoing internal program prioritization and expected achievement of a milestone required for an earn-out payment associated with a specific license. Changes in the fair value of the liability for contingent consideration are recognized as a non-cash fair value gain through other income. In the second quarter of 2025, the remaining contingent consideration of $8.7 million was paid in its entirety. In-Process Research and Development Assets As discussed in Note 7, the estimated fair values in support of the TetraGenetics full impairment charge in 2024 were categorized within Level 3 of the fair value hierarchy and were determined using an income-based approach, which was based on a probability-adjusted present value of the future estimated after-tax cash flows attributable to the intangible assets. The significant assumptions inherent in estimating the fair values, from the perspective of a market participant, include a probability-adjusted success rate of its continued development through to clinical trials, future revenue, operating and development costs, milestone and regulatory success, obsolescence, and profitability. A de-risked discount rate of 12.8% for TetraGenetics was used to present value the probability of success risk adjusted after-tax cash flows attributable to the IPR&D. Marketable Securities As part of the Company’s cash management strategy, the Company holds a diversified portfolio of high credit quality marketable securities that are available to support the Company’s operations. As of December 31, 2025, our marketable securities were rated A- (or its equivalent) or higher by at least two of the major rating agencies with a weighted average life of approximately 0.5 years. Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period. The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
| Fair Value Measurements at December 31, 2024:
| Level 1 |  | Level 2 |  | Level 3 |  | Total
Marketable securities |  |  |  |  |  |  |
U.S. government agencies | $ | 90,601 |  |  | $ | — |  |  | $ | — |  |  | $ | 90,601 |
Certificate of deposit | — |  |  | 90,632 |  |  | — |  |  | 90,632 |
Commercial paper | — |  |  | 53,757 |  |  | — |  |  | 53,757 |
Corporate bonds | — |  |  | 130,088 |  |  | — |  |  | 130,088 |
Asset backed securities | — |  |  | 104,211 |  |  | — |  |  | 104,211 |
| $ | 90,601 |  |  | $ | 378,688 |  |  | $ | — |  |  | $ | 469,289 |
| Fair Value Measurements at December 31, 2025:
| Level 1 |  | Level 2 |  | Level 3 |  | Total
Marketable securities |  |  |  |  |  |  |
U.S. government agencies | $ | 66,074 |  |  | $ | — |  |  | $ | — |  |  | $ | 66,074 |
Certificate of deposit | — |  |  | 106,381 |  |  | — |  |  | 106,381 |
Commercial paper | — |  |  | 25,776 |  |  | — |  |  | 25,776 |
Corporate bonds | — |  |  | 145,942 |  |  | — |  |  | 145,942 |
Asset backed securities | — |  |  | 61,140 |  |  | — |  |  | 61,140 |
| $ | 66,074 |  |  | $ | 339,239 |  |  | $ | — |  |  | $ | 405,313 |

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration